Aromatase inhibitors: Past, present and future

Molecular and Cellular Endocrinology

Volumn 178, Issue 1-2, 2001, Pages 117-131

  Séralini, Gilles Eric ^a   Moslemi, Safa ^a  

^a UNIVERSITÉ DE CAEN   (France)

Author keywords

Aromatase; Cancer; Cytochrome P450; Enzymatic inhibition; Reproduction; Steroidogenesis

Indexed keywords

AROMATASE; AROMATASE INHIBITOR; CYTOCHROME P450; ESTROGEN; MESSENGER RNA;

CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; ESTROGEN ACTIVITY; GYNECOMASTIA; HUMAN; MALE GENITAL SYSTEM FUNCTION; MAMMAL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AROMATASE; AROMATASE INHIBITORS; CATALYTIC DOMAIN; ENZYME INHIBITORS; ESTROGENS; FEMALE; FLAVONOIDS; HUMANS; MALE; MICE; MICE, KNOCKOUT; MUTAGENESIS, SITE-DIRECTED; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; STEROIDS;

EID: 0035912880     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(01)00433-6     Document Type: Conference Paper

References (140)

1. Aromatase inhibition by 4-thiosubstituted-4-androstene-3,17-dione derivatives
2. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens
3. The effect of the aromatase inhibitor fadrozole and two polynuclear aromatic hydrocarbons on sex steroid secretion by ovarian follicles of coho salmon
4. Hormonal effects of MPV-2213ad, a new selective aromatase inhibitor, in healthy male subjects. A phase I study
5. Immunohistochemical localization of cytochrome P450 aromatase in equine gonads
6. Equine cytochrome P450 aromatase exhibits an estrogen hydroxylase activity in vitro
7. Evidence for new non-steroidal human aromatase inhibitors and comparison with equine aromatase inhibition for an understanding of the mammalian active site
8. PAAn-1b and PAAn-E: two phosphorothioate antisense oligodeoxynucleotides inhibit human aromatase gene expression
9. MR 20492 and MR 20494: two indolizinone derivatives that strongly inhibit human aromatase
10. Inhibition of human placental aromatase by mefloquine
11. Effect of ketoconazole on placental aromatase, 3β-hydroxysteroid dehydrogenase-Isomerase and 17β-hydroxysteroid dehydrogenase
12. Imidazole derivatives of pyrrolidonic and piperidonic acids as potential inhibitors of human placental aromatase in vitro
13. Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study
14. Dual regulation of promoter II- and promoter 1f-derived cytochrome P450 aromatase transcripts in equine granulosa cells during human chorionic gonadotropin-inuduced ovulation: a novel model for the study of aromatase promoter switching
15. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer
16. Inactivation of aromatase in vitro by 4-hydroxy-4-androstenedione-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo
17. 7 alpha-substituted androstenedione as effective in vitro and in vivo inhibitors of aromatase
18. R 75251, a new inhibitor of steroid biosynthesis
19. Liarozole
20. Reversible inhibition of human placental microsomal aromatase by CGS 18320B and other non-steroidal compounds
21. Treatment of gynecomastia and hypogonadism in disorders of excessive estrogen formation using an aromatase inhibitor
22. Aromatase inhibition reduces dendritic growth in a sexually dimorphic rat spinal nucleus
23. Webster, The Arimidex Study Group, a phase III trial comparing anastrozole (1 and 10 mg), a potent and selective aromatase inhibitor, with advanced breast carcinoma
24. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes
25. Estrogens and male reproduction
26. The oetrogen sources in the testis and the reproductive tract of the male
27. A new antiestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474
28. 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer
29. 10β-Propynyl-substituted steroid: mechanism-based enzyme-activated irreversible inhibitors of estrogen biosynthesis
30. Aromatase deficiency caused by a novel P450arom gene mutation: impact of absent estrogen production on serum gonadotropin concentration in a boy
31. The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer
32. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer
33. Exemestane (FCE24304), a new steroidal aromatase inhibitor
34. Second generation aromatase inhibitor 4-hydroxyandrostenedione
35. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer
36. Use of aromatase inhibitors in precocious puberty
37. Characterization of mice deficient in aromatase (ArKO) of targeted disruption of the cyp19 gene
38. Overexpression of aromatase leads to development of testicular Leydig cell tumors
39. Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds
40. Structure-function relationships of human aromatase cytochrome P450 using molecular modeling and site directed mutagenesis
41. A three-dimensional model of aromatase cytochrome P450
42. Certain aspects of molecular endocrinology that relate to the influence of dietary factors on the pathogenesis of prostate cancer
43. Inhibition of human drug metabolizing cytochrome P450 by anastrozole, a potent and selective inhibitor of aromatase
44. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer
45. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy
46. Pyridyl-substituted tetrahydrocyclopropa[a]naphthalenes: highly active and selective inhibitors of P450 arom
47. 1-Methyl-1,4-androstadiene-3,17-dione (SH 489): characterization of an irreversible inhibitor of estrogen biosynthesis
48. A role for oestrogens in the male reproductive system
49. Regulation of sex-specific formation of oestrogen in brain development: endogenous inhibitors of aromatase
50. Aromatase inhibition by flavonoids
51. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma
52. Inhibition of aromatase activity by flavonoids
53. Biochemical and endocrine properties of a mechanism-based inhibitor of aromatase
54. Kinetic properties of aromatase mutants Pro308Phe, Asp309Asn, and Asp309Ala and their interactions with aromatase inhibitors
55. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study
56. Aromatase inhibitors: synthesis, biological activity, and structure of 1,2-imidazolylmethylcyclopentanol derivatives
57. Inhibition of estrogen synthetase (aromatase) by 4-cyclohexylaniline
58. Inhibition of estrogen synthetase (aromatase) by flavones
59. 6α-Fluorotestosterone: a nonaromatizable androgen inhibitor of aromatase cytochrom P450
60. Inhibition of aromatase cytochrome P-450 (estrogen synthetase) by derivatives of alpha-naphthoflavone
61. Enantioselectivity of some 1-(benzofuran-2-yl)-1-(1-H-imidazol-1-yl) alkanes as inhibitors of P450arom
62. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens
63. SNA-60-367, new peptide enzyme inhibitors against aromatase
64. Selective aromatase inhibition by pyridoglutethimid, an analogue of aminoglutethimide
65. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer
66. At the cutting edge - intracrinology
67. Structure-activity relationship and binding model of novel aromatase inhibitors
68. A detailed molecular model for human aromatase
69. Aromatase and 17-beta-hydroxysteroid dehydrogenase inhibition by flavonoids
70. Cytotoxicity and aromatase (CYP19) activity modulation by organochlorines in human placental JEG-3 and JAR choriocarcinoma cells
71. Alternative splicing in the coding region of the cytochrome P450 aromatase gene in male rat germ cells
72. 7-Substituted 1,4,6-androstatriene-3,17-dione as enzyme-activated irreversible inhibition of aromatase
73. Synthesis of new steroidal isoxazoles: inhibitors of estrogen synthase
74. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment
75. The effects of aromatase inhibitors and antiestrogens in the nude mouse model
76. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats
77. Inhibition and inactivation of estrogen synthetase (aromatase) by fluorinated substrate analogues
78. In vitro bioassay of non-steroidal phytoestrogens
79. Imidazol antimycotics: inhibitors of steroid aromatase
80. Substrate-induced inactivation of aromatase by allenic and acetylenic steroids
81. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer
82. Aromatase inhibitors-where are we now?
83. Inhibition and inactivation of equine aromatase by steroidal and non-steroidal compounds. A comparison with human aromatase inhibition
84. Different in vitro metabolism of 7α-methyl-19-nortestosterone by human and equine aromatases
85. Purification and characterization of equine testicular cytochrome P-450aromatase. Comparison with the human enzyme
86. Structure-function relationships for equine and human aromatases: a comparative study
87. ERβ: identification and characterization of a novel human estrogen receptor
88. 6 Alpha,7 alpha-cyclopropane derivatives of androst-4-ene: a novel class of competitive aromatase inhibitors
89. 6-Alkyl-and 6-arylandrost-4-ene-3,17-diones as aromatase inhibitors. Synthesis and structure-activity relationships
90. Studies on aromatase inhibition with 4-androstene-3,6,17-trione: its 3 beta-reduction and time-dependent irreversible binding to aromatase with human placental microsomes
91. 19-Hydroxy-4-androstene-17-one: potential competitive inhibitor of estrogen biosynthesis
92. Time-dependent inactivation of human placental aromatase by bromoacetoxy-4-androsten-3-ones in presence of reduced nicotinamide adenine dinuleotide phosphate (NADPH)
93. Competitive inhibition and suicide inactivation of human placental aromatase by androst-4-ene-3,6-dione derivatives and 3a-methoxyandrost-4-ene-6,17-dione
94. Synthesis and biochemical studies of 16- or 19-substituted androst-4-enes as aromatase inhibitors
95. Synthesis of androst-5-en-7-ones and androsta-3,5-dien-7-ones and their related 7-deoxy analogs as conformational and catalytic probes for the active site of aromatase
96. Aromatization of 19-oxygenated androst-4-ene-3,6,17-triones with human placental microsomes
97. 19-oxygenated derivatives of androst-4-ene-6,17-dione and androst-5-ene-4,17-dione as catalytic probes for the active site of aromatase
98. Three-dimensional quantitative structure-activity relationships of steroid aromatase inhibitors
99. Synthesis, structure elucidation, and biochemical evaluation of 7 alpha- and 7 beta-arylaliphatic-substituted androst-4-ene-3,17-diones as inhibitors of aromatase
100. Stereochemistry of the functional group determines the mechanism of aromatase inhibition by 6-bromoandrostenedione
101. Multiple functions of aromatase and the active site structure; aromatase is the placental estrogen 2-hydroxylase
102. Inhibition of aromatase (P450Arom) by some 1-(benzofuran-2-ylmethyl)imidazoles
103. Effects of flavonoids on aromatase activity, an in vitro study
104. Arimidex: a potent and selective fourth-generation aromatase inhibitor
105. Comparative molecular field analysis of non-steroidal aromatase inhibitors related to fadrozole
106. Comparative molecular field analysis of non-steroidal aromatase inhibitors: an extended model for two different structural classes
107. Impairment of spermatogenesis in mice lacking a functional aromatase (cyp 19) gene
108. Aminoglutethimide inhibits extraglandular estrogen production in post-menopausal women with breast carcinoma
109. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma
110. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor
111. Phytoestrogens: potential endocrine disruptors in males
112. Intratumoral aromatase in human breast, endometrial, and ovarian malignancies
113. Studies on the mechanism of estrogen biosynthesis. 8. The development of inhibitors of the enzyme system in human placenta
114. Rainbow trout, Oncorhynchus mykiss, as a model for aromatase inhibition
115. Expression of the CYP19 (aromatase) gene: an unusual case of alternative promoter usage
116. Potent enzyme-activated inhibition of aromatase by a 7α-substituted C19 steroid
117. Design and synthesis of a new type of non steroidal human aromatase inhibitors
118. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A
119. Treatment of sever postmenopausal endometriosis with an aromatase inhibitor
120. Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility
121. Aromatase inhibitors - mechanisms for non-steroidal inhibitors
122. R 76713 and enantiomers: selective, nonsteroidal inhibitors of the cytochrome P450-dependent oestrogen synthesis
123. Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats
124. Inhibition of 7,12-dimethylbenz(a)anthracene and N-nitrosomethylurea-induced rat mammary cancer by dietary flavonol quercetin
125. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes
126. Flavonoids. 8. Synthesis and antifertility and estrogen receptor binding activities of coumarins and delta 3-isoflavenes
127. Preparation of an activity-inhibiting monoclonal antibody against human placental aromatase cytochrome P450
128. Formestan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer
129. R 76713, a new specific non-steroidal aromatase inhibitor
130. 'Slow-binding' sixth-ligand inhibitors of cytochrome P-450 aromatase. Studies with 19-thiomethyl- and 19-azido-androstenedione
131. Two organochlorine pesticides, toxaphene and chlordane, are antagonists for estrogen-related receptor alpha-1 orphan receptor
132. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers
133. 14α-Hydroxyandrost-4-ene-3,6,17-trione as a mechanical-based irreversible inhibitor of estrogen biosynthesis
134. Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell-culture
135. A new irreversible aromatase inhibitor, 6-methylandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors
136. Stimulation of aromatase P450 promoter (II) activity in endoometriosis and its inhibition in endo metrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element
137. Structure-function studies of human aromatase by site-directed mutagenesis: kinetic properties of mutants Pro-308-Phe, Tyr-361-Phe, Tyr-361-Leu, and Phe-406-Arg
138. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor